Skip to main content
SINOTHERAPEUTICS INC. logo

SINOTHERAPEUTICS INC. — Investor Relations & Filings

Ticker · 688247 ISIN · CNE100005PL9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 394 across all filing types
Latest filing 2026-05-28 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688247

About SINOTHERAPEUTICS INC.

https://www.sinotph.com/en/

Sinotherapeutics Inc. is a pharmaceutical company specializing in the research, development, and commercialization of complex generic drugs and innovative drug delivery systems. The company focuses on high-barrier formulations, particularly oral solid dosage forms with modified-release or controlled-release profiles. Utilizing advanced technology platforms, Sinotherapeutics develops products designed to improve patient compliance and therapeutic outcomes. Its operations encompass the full lifecycle of drug development, from formulation design and clinical evaluation to large-scale manufacturing under global quality standards. The company maintains a robust pipeline targeting various therapeutic areas, including cardiovascular diseases, central nervous system disorders, and metabolic conditions. Sinotherapeutics aims to provide high-quality, affordable medications by leveraging its expertise in complex chemistry and pharmaceutical engineering.

Recent filings

Filing Released Lang Actions
关于董事会完成换届选举、聘任高级管理人员、证券事务代表及核心技术人员离任的公告
Board/Management Information Classification · 92% confidence The document is an official announcement by Shanghai Xuantai Pharmaceutical Technology Co., Ltd. detailing the outcomes of board of directors re-election, election of board chairman and committee members, appointment of senior management (general manager, deputy general managers, financial officer, board secretary), appointment of the securities affairs representative, and the departure of certain core technical personnel. This clearly falls under corporate governance and management changes. Therefore, it should be classified as Board/Management Information (Code: MANG).
2026-05-28 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 94% confidence The document is titled “2025年年度股东会决议公告” and provides detailed results of each resolution voted on at the Annual General Meeting, including vote counts, percentages, quorum, and certification. There are no financial statements or requests for votes (proxy materials), only the official announcement of shareholder voting outcomes. This matches the Declaration of Voting Results & Voting Rights Announcements category.
2026-05-28 Chinese
上海市锦天城律师事务所关于上海宣泰医药科技股份有限公司2025年年度股东会之法律意见书
Regulatory Filings Classification · 80% confidence The document is a legal opinion letter (“法律意见书”) issued by a law firm on the legality of the company’s 2025 annual general meeting procedures, quorum, convening, and voting process. It does not itself present financial data, proxy materials, voting results, or a management narrative of results. It is not an AGM presentation or the actual Annual Report, nor is it a proxy solicitation statement or voting results announcement. Rather, it is a compliance/legal opinion attached to a regulatory event. Under the guidelines, this type of standalone compliance/legal opinion should be classified as a general Regulatory Filing (RNS).
2026-05-28 Chinese
国泰海通证券股份有限公司关于上海宣泰医药科技股份有限公司部分募集资金投资项目延期的核查意见
Regulatory Filings Classification · 93% confidence The document is a sponsor’s verification opinion (‘核查意见’) on the postponement of previously raised‐fund investment projects, filed to comply with the Shanghai Sci‐Tech Innovation Board’s fundraising use rules. It is not a financial report (10-K, IR, ER), not a board/management change notice, not a capital raise or share‐issue announcement, nor an earnings call or ESG report. It is a regulatory compliance filing and thus best fits the ‘Regulatory Filings’ (RNS) category.
2026-05-25 Chinese
2025年年度股东会会议资料
AGM Information Classification · 88% confidence The document is clearly titled “2025年年度股东会会议资料” (2025 Annual General Meeting Meeting Materials) for Shanghai Yitai Pharmaceutical Technology Co., Ltd. It contains the AGM notice, agenda, detailed proposals for dividends, board elections, governance rule amendments, audit appointments, etc.—all typical of annual shareholders’ meeting materials. It is not a financial report or earnings release but rather the materials provided to shareholders for the AGM. Therefore, it should be classified as AGM Information (AGM-R).
2026-05-22 Chinese
国泰海通证券股份有限公司关于上海宣泰医药科技股份有限公司2025年度持续督导工作现场检查报告
Regulatory Filings Classification · 82% confidence The document is a ‘现场检查报告’ prepared by the sponsor (Guotai Huatong) under Shanghai Stock Exchange and CSRC rules concerning continuous supervision of an issuer. It is a regulatory compliance report filed to the exchange, not an annual or interim financial report, not an audit opinion, not a board change announcement, nor any other specific category. It belongs in the general Regulatory Filings (RNS) fallback category.
2026-05-20 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.